Loading
3 standard-of-care settings across 3 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Localised LAMN / adenocarcinoma | Appendicectomy (LAMN without perforation) or right hemicolectomy (adenocarcinoma, goblet cell); adjuvant chemotherapy for node-positive adenocarcinoma by colorectal analogy. | NCCN · Category 2A | 82 |
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | High-grade or unresectable peritoneal disease | FOLFOX/CAPOX ± bevacizumab; systemic chemotherapy has no proven benefit in low-grade disease (randomised 2024). | 98 |
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Pseudomyxoma peritonei / peritoneal disease | Cytoreductive surgery with HIPEC at a peritoneal-surface-malignancy centre; repeat CRS for recurrence when feasible. | PSOGI consensus (2016); Chicago Consensus (2020) | 85 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.